| Literature DB >> 30976107 |
Jessica Vamathevan1, Dominic Clark2, Paul Czodrowski3, Ian Dunham4, Edgardo Ferran2, George Lee5, Bin Li6, Anant Madabhushi7,8, Parantu Shah9, Michaela Spitzer4, Shanrong Zhao10.
Abstract
Drug discovery and development pipelines are long, complex and depend on numerous factors. Machine learning (ML) approaches provide a set of tools that can improve discovery and decision making for well-specified questions with abundant, high-quality data. Opportunities to apply ML occur in all stages of drug discovery. Examples include target validation, identification of prognostic biomarkers and analysis of digital pathology data in clinical trials. Applications have ranged in context and methodology, with some approaches yielding accurate predictions and insights. The challenges of applying ML lie primarily with the lack of interpretability and repeatability of ML-generated results, which may limit their application. In all areas, systematic and comprehensive high-dimensional data still need to be generated. With ongoing efforts to tackle these issues, as well as increasing awareness of the factors needed to validate ML approaches, the application of ML can promote data-driven decision making and has the potential to speed up the process and reduce failure rates in drug discovery and development.Entities:
Mesh:
Year: 2019 PMID: 30976107 PMCID: PMC6552674 DOI: 10.1038/s41573-019-0024-5
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN: 1474-1776 Impact factor: 84.694